Skip to main content
Premium Trial:

Request an Annual Quote

Whitehead Institute, Illumina


MIT’s Whitehead Institute is offering primer sets for its human promoter-region arrays, said Thomas Volkert, director of the institute’s microarray core facility.

The institute will provide an aliquot of primer, enough for 5-10 PCR reactions to amplify the fragments necessary for DNA appropriate to create the probes for the arrays, for $25,000, he said. The institute doesn’t sell microarrays.

The primers are surplus from the institute’s activities and will be sold to recover the purchase costs, he said.

The promoter-region arrays are based on research involving RNA in transcription and based around patented technology developed for promoter-region arrays. The technique involves the mapping of binding sites of transcription factors, upstream of a gene, which regulate a broad array of functions and interact with DNA.

The genes selected for the human arrays include the best annotated arrays, found by going through databases with the criteria for selection being a known function.

The institute will also provide informatics on the genes and quality control information.


Illumina introduced its Sentrix BeadChip platform, which is based on a 1x3 glass slide and incorporates the company’s bead array technology.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.